View Author
patient group study treatment survival hospital leukemia blood myeloid leukemia cycle induction therapy remission analysis cytogenetic count promyelocytic leukemia expression table trial chemotherapy factor myeloid month prognostic relapse 3-itd result number cd 56 expression flt 3-itd response death abnormality center value outcome university all-trans retinoic acid signi ratio promyelocytic wbc count square meter cytarabine event-free survival myeloma spain event-free level erasmus mc erasmu effect prognostic factors daunorubicin sample 16ink mutation high-dose randomized j clin oncol diagnosis thalidomide flt 3-itd ratio platelet erasmus university universitario square volume p 16ink expression figure meter 2011. probe consolidation multivariate analysis performance status signi ficantly performance 109/
10 Most Recent Publications
|
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
(Article)
Helm, L.H. van der Alhan, C. Wegman, J. Libourel, W.J. Luykx-de Bakker, S.A. Minnema, M.C. Brouwer, R.E. Croon-de Boer, F. Eefting, M. Jie, K.S-G. Loosdrecht, A.A. van de Koedam, J. Wijermans, P. Veeger, N.J.G.M. Vellenga, E. Huls, G. Marwijk Kooy, M. van Schaafsma, R. Biemond, B.J. Beeker, A. Hoogendoorn, M. Rees, B.P. van de Weerdt, O. |
2011-12-01
|
|
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
(Article)
Montesinos, P. González, M.B. Manso, F. Vellenga, E. Löwenberg, B. Sanz, M.A. |
2011-10-01
|
|
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: Relevance of mutated NPM1 and FLT3-ITD
(Article)
Jonge, H.J.M. de Valk, P.J.M. Bont, E.S.J.M. de Schuringa, J.J. Ossenkoppele, G.J. Vellenga, E. Huls, G. |
2011-09-01
|
|
Cytarabine dose for acute myeloid leukemia
(Article)
Löwenberg, B. Pabst, T. Greef, G.E. de Verdonck, L.F. Schaafsma, M.R. Gregor, M. Theobald, M. Schanz, U. Maertens, J. Ossenkoppele, G.J. Vellenga, E. Putten, W. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Biemond, B.J. Gratwohl, A. |
2011-03-17
|
|
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
(Article)
Montesinos, P. Rayón, C. Rivas, C. Tormo, M. Rubio, V. Bueno, J. Manso, F. Milone, G. Serna, J. De La Pérez, I. Pérez-Encinas, M. Krsnik, I. Vellenga, E. Ribera, J.M. Sanz, M.A. Escoda, L. Löwenberg, B. Brunet, S. González, J. González, M.B. Holowiecka, A. Esteve, J. Bergua, J.M. González, J.D. |
2011-02-10
|
|
Gemtuzumab ozogamicin as postremission treatment inAMLat 60 years of age or more: results of a multicenter phase 3 study
(Article)
Löwenberg, B. Beck, J.A. Biemond, B.J. Vellenga, E. Breems, D.A. Muijnck, H. de Schaafsma, R. Verhoef, G. Döhner, H. Gratwohl, A. Pabst, T. Ossenkoppele, G.J. Graux, C. Maertens, J. Putten, W.L.J. van Schouten, H.C. Verdonck, L.F. Ferrant, A. Sonneveld, P. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2010-04-01
|
|
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
(Article)
Cervera, J. Montesinos, P. Milone, G. La Serna, J. de Rivas, C. González, J.D. Tormo, M. Amutio, E. Brunet, S. Löwenberg, B. Sanz, M.A. Hernandez-Rivas, J.M. Calasanz, M.J. Aventín, A. Ferro, M.T. Luño, E. Sánchez, J. Vellenga, E. Rayón, C. |
2010-03-01
|
|
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
(Article)
Lokhorst, H.M. Holt, B. van der Wittebol, S. Delforge, M. Berenschot, H. Bos, G.M. Jie, K.S-G. Sinnige, H. Marwijk Kooy, M. van Joosten, P. Minnema, M.C. Ammerlaan, R. van Zweegman, S. Sonneveld, P. Vellenga, E. Croockewit, S. Oers, M.H.J. van von dem Borne, P.A. Wijermans, P.W. Schaafsma, R. de Weerdt, O. |
2010-02-11
|
|
AML at older age: Age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance
(Article)
Jonge, H.J.M. de Bont, E.S.J.M. de Huls, G. Valk, P.J.M. Schuringa, J.J. Kies, M. Woolthuis, C.M. Delwel, H.R. Veeger, N.J.G.M. Vellenga, E. Löwenberg, B. |
2009-11-19
|
|
High-dose daunorubicin in older patients with acute myeloid leukemia
(Article)
Löwenberg, B. Ossenkoppele, G.J. Biemond, B.J. Vellenga, E. Marwijk Kooy, M. van Verdonck, L.F. Beck, J.A. Döhner, H. Gratwohl, A. Pabst, T. Verhoef, G.E.G. Putten, W.L.J. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Maertens, J. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2009-09-24
|
